Compare UTMD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTMD | SGMT |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.5M | 169.4M |
| IPO Year | 1994 | 2021 |
| Metric | UTMD | SGMT |
|---|---|---|
| Price | $63.80 | $6.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 6.4K | ★ 2.7M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $38,520,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $78.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $52.00 | $3.15 |
| 52 Week High | $71.81 | $11.41 |
| Indicator | UTMD | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 48.51 |
| Support Level | $60.23 | $6.07 |
| Resistance Level | $64.21 | $7.20 |
| Average True Range (ATR) | 1.42 | 0.62 |
| MACD | -0.36 | -0.15 |
| Stochastic Oscillator | 16.39 | 1.32 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.